Benefits and risks of the subcutaneous immunotherapy with acari extracts in allergic rhinoconjunctivitis and bronchial asthma
The records of patients from the Allergology Service in the Previsora Policlinic, Camagüey were revised to evaluate benefits and risks of the subcutaneous immunotherapy (ITSC) with extracts of acari. The study was observational, analytic and retrospective of cases and controls in allergic rhinoco...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Finlay Ediciones
2014-12-01
|
| Series: | VacciMonitor |
| Subjects: | |
| Online Access: | http://scielo.sld.cu/scielo.php?script=sci_pdf&pid=S1025-028X2014000300007&lng=es&nrm=iso&tlng=es |
| Summary: | The records of patients from the Allergology Service in the Previsora Policlinic, Camagüey were
revised to evaluate benefits and risks of the subcutaneous immunotherapy (ITSC) with extracts
of acari. The study was observational, analytic and retrospective of cases and controls in allergic
rhinoconjunctivitis and bronchial asthma. A total of 160 subjects, older than 18 years old, were
chosen. Eighty out of them had already received ITSC with dose increase during 13 weeks and
maintenance with monthly injections during 18 months. A total of 80 patients who only received
prevention measures and medications during the crises were paired. Questionnaires were
applied for quality of rhinoconjunctivitis life and asthma, about the consumption of medications
and the frequency of the crises. The adverse events were measured, as they were local and
systemic to the cutaneous tests, to the ITSC and the different pharmacological treatments. There
was a significant increase of the punctuation of life quality questionnaires, (p=0.011). The
consumption of medications decreased in both the cases and the controls, without significant
differences (p=0.083). The frequency of the rhinitis and asthma crises decrease in the group of
ITSC (p=0.029). Slight local and systemic reactions were reported in both groups with Odds
ratio (OR)=2.029 in the ITSC group, with a 95% confidence interval of 1.114–3.967 (p=0.019).
The results show that the subcutaneous immunotherapy with acari offers benefits and few risks
to patients with allergic rhinoconjunctivitis and asthma. |
|---|---|
| ISSN: | 1025-028X 1025-0298 |